Simulations Plus Enters New Strategic Collaboration to Discover Anticancer Therapies Through Its AI-Driven Drug Design TechnologyBusiness Wire • 03/28/23
Simulations Plus Sets Date for Second Quarter Fiscal Year 2023 Earnings Release and Conference CallBusiness Wire • 03/21/23
Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel CompoundsBusiness Wire • 03/15/23
Simulations Plus to Present at Raymond James 44th Annual Institutional Investors ConferenceBusiness Wire • 02/28/23
Simulations Plus and Global Agrochemicals Leader to Collaborate on Machine Learning ModelsBusiness Wire • 02/16/23
Simulations Plus: Differentiated Offering For Speculators Of Clinical-Stage AssetsSeeking Alpha • 02/09/23
Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software InfrastructureBusiness Wire • 01/12/23
Simulations Plus Sets Date for First Quarter Fiscal Year 2023 Earnings Release and Conference CallBusiness Wire • 12/19/22
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship ProgramBusiness Wire • 11/10/22
Simulations Plus 25th Anniversary Celebration Concludes with $25,000 Gift to Nonprofit, Girls Who CodeBusiness Wire • 11/03/22
Simulations Plus and the University of Florida Awarded New FDA Contract to Support Development and Regulatory Assessment of Inhaled ProductsBusiness Wire • 11/02/22